Showing 1,701 - 1,720 results of 32,032 for search '(( 50 ((we decrease) OR (((a decrease) OR (nn decrease)))) ) OR ( a step decrease ))', query time: 0.94s Refine Results
  1. 1701

    IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors by Alexandra Cousido-Siah (777034)

    Published 2016
    “…Next, by means of IC<sub>50</sub> measurements, X-ray crystallography, WaterMap analysis, and advanced binding free energy calculations with a quantum-mechanical (QM) approach, we have studied their structure–activity relationship (SAR) against both enzymes. …”
  2. 1702

    Gene clustering identifies up- and down-regulated groups that control development, pluripotency, and cell division. by Michael Shelton (382572)

    Published 2019
    “…<p>Pluripotent H9 hESCs were differentiated for 50 days as previously described [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0222946#pone.0222946.ref012" target="_blank">12</a>], beginning with high (7.5 μM or 10 μM) CHIR99021 concentrations. mRNA samples from the indicated time points were subjected to gene expression profiling. …”
  3. 1703
  4. 1704
  5. 1705

    Data Sheet 1_Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: a retrospective analysis... by Hiroyuki Koami (3878434)

    Published 2025
    “…</p>Results<p>Of 2,726 patients who met the inclusion criteria, logistic regression models demonstrated that decreased CH50 is a significant predictor of 180-day mortality (OR: 0.98-0.99). …”
  6. 1706

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  7. 1707

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  8. 1708

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  9. 1709

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  10. 1710

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  11. 1711

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  12. 1712

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  13. 1713

    A Minor (<50%) Signet-Ring Cell Component Associated with Poor Prognosis in Colorectal Cancer Patients: A 26-Year Retrospective Study in China by Yinuo Tan (705777)

    Published 2015
    “…<div><p>Background</p><p>We performed a retrospective study to determine the cancer-specific survival of colorectal cancer patients with a component of signet-ring cells or mucin comprising < 50% of the tumor mass.…”
  14. 1714
  15. 1715
  16. 1716
  17. 1717
  18. 1718
  19. 1719

    Grouping codes according to drivers and themes. by Jennie Ochshorn (21300213)

    Published 2025
    “…All approaches offer an automated component as the first step (a mobile app) and either an in-person, virtual reality (VR), or video telehealth session as the second step. …”
  20. 1720

    Intervention models and descriptions. by Jennie Ochshorn (21300213)

    Published 2025
    “…All approaches offer an automated component as the first step (a mobile app) and either an in-person, virtual reality (VR), or video telehealth session as the second step. …”